Neurocrine Acquires Soleno Therapeutics for $2.9 Billion, Expanding Rare Disease Portfolio

Neurocrine Biosciences is acquiring Soleno Therapeutics for approximately $2.9 billion in an all-cash deal to secure its flagship drug, VYKAT XR.

This acquisition allows Neurocrine to diversify beyond its main product, INGREZZA, and strengthen its pipeline in rare neuroendocrine diseases using its significant cash reserves.

The deal was driven by the successful FDA approval and rapid commercial uptake of VYKAT XR, which de-risked the asset and demonstrated its significant market potential.

Neurocrine Biosciences has announced its acquisition of Soleno Therapeutics for approximately $2.9 billion in an all-cash deal.

This move is a significant strategic step for Neurocrine. The company has been looking to diversify its revenue beyond its flagship drug, INGREZZA. By acquiring Soleno, Neurocrine gains VYKAT XR, a groundbreaking treatment for a rare disease, which provides a new, durable source of income. With over $2.5 billion in cash, Neurocrine was well-positioned to make such a decisive, all-cash offer.

So, why was Soleno such an attractive target? The reason is simple: it successfully turned a promising drug into a commercial reality. The journey began with the FDA's approval of VYKAT XR in March 2025, the first-ever treatment for hyperphagia (insatiable hunger) associated with Prader-Willi Syndrome (PWS). This approval removed the single biggest risk associated with the drug.

What followed was a masterclass in execution. First, Soleno achieved a strong commercial launch, reporting nearly 900 active patients and reaching profitability within just nine months. This demonstrated real-world demand and a clear path to growth. Second, with European approval also under review, the drug offered significant potential for international expansion. Third, this proven success story aligned perfectly with Neurocrine's stated goal of acquiring assets for "strong, sustainable growth."

This acquisition also reflects a broader trend in the healthcare industry. Large pharmaceutical companies have been actively pursuing "string-of-pearls" acquisitions—smaller, strategic buyouts of companies with promising, de-risked assets, especially in fields like neurology and rare diseases. Soleno, with its FDA-approved, commercially successful drug, fit this profile perfectly.

Prader-Willi Syndrome (PWS): A rare genetic disorder that results in a number of physical, mental, and behavioral problems. A key feature is a constant sense of hunger (hyperphagia).
Hyperphagia: An abnormally great desire for food; insatiable appetite.
Merger Arbitrage: An investment strategy that seeks to profit from the price difference between a stock's trading price and the valuation offered in an acquisition.

Neurocrine Acquires Soleno Therapeutics for $2.9 Billion, Expanding Rare Disease Portfolio

Neurocrine Biosciences is acquiring Soleno Therapeutics for approximately $2.9 billion in an all-cash deal to secure its flagship drug, VYKAT XR.

This acquisition allows Neurocrine to diversify beyond its main product, INGREZZA, and strengthen its pipeline in rare neuroendocrine diseases using its significant cash reserves.

The deal was driven by the successful FDA approval and rapid commercial uptake of VYKAT XR, which de-risked the asset and demonstrated its significant market potential.

Neurocrine Biosciences has announced its acquisition of Soleno Therapeutics for approximately $2.9 billion in an all-cash deal.

Prader-Willi Syndrome (PWS): A rare genetic disorder that results in a number of physical, mental, and behavioral problems. A key feature is a constant sense of hunger (hyperphagia).
Hyperphagia: An abnormally great desire for food; insatiable appetite.
Merger Arbitrage: An investment strategy that seeks to profit from the price difference between a stock's trading price and the valuation offered in an acquisition.